Oncology Dealmaking is Becoming More Surgical
Oncology remains the largest segment in global pharma, accounting for around $241bn in 2025 prescription drug revenues. But portfolio momentum is fragmenting, and the next growth cycle looks materially different from the last one. We address many of the big issues in the oncology space in the new Evaluate Spotlight episode which is available here. […]
